Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DF6215 Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT06108479Phase 1Completed
- Sponsor
- Dragonfly Therapeutics
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons
- Countries
- 3
01
Overview
Phase 1, open-label trial of DF6215 in solid tumor, melanoma and ovarian cancer (9 arms), sponsored by Dragonfly Therapeutics. Primary endpoints: Maximum Tolerated Dose at 42 days, Safety and Tolerability up to 2 years and 1 more. Started Nov 2023; status: completed.
02
Drugs
DF6215
03
Conditions
solid tumormelanomaovarian cancer
Beyond the preview
Go deeper on NCT06108479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06108479.